Practical considerations for the use of SGLT-2 inhibitors in the Asia–Pacific countries—An expert consensus statement

Adrian Liew, Aida Lydia, Bien J. Matawaran, Paweena Susantitaphong, Huong Thi Bich Tran, Lee Ling Lim

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)


Recent clinical studies have demonstrated the effectiveness of SGLT-2 inhibitors in reducing the risks of cardiovascular and renal events in both patients with and without type 2 diabetes mellitus. Consequently, many international guidelines have begun advocating for the use of SGLT-2 inhibitors for the purpose of organ protection rather than as simply a glucose-lowering agent. However, despite the consistent clinical benefits and available strong guideline recommendations, the utilization of SGLT-2 inhibitors have been unexpectedly low in many countries, a trend which is much more noticeable in low resource settings. Unfamiliarity with the recent focus in their organ protective role and clinical indications; concerns with potential adverse effects of SGLT-2 inhibitors, including acute kidney injury, genitourinary infections, euglycemic ketoacidosis; and their safety profile in elderly populations have been identified as deterring factors to their more widespread use. This review serves as a practical guide to clinicians managing patients who could benefit from SGLT-2 inhibitors treatment and instill greater confidence in the initiation of these drugs, with the aim of optimizing their utilization rates in high-risk populations.

Original languageEnglish
Pages (from-to)415-424
Number of pages10
Issue number8
Publication statusAccepted/In press - 2023


  • acute kidney injury
  • chronic kidney disease
  • ketosis
  • sodium-glucose transporter 2 inhibitors
  • urinary tract infections


Dive into the research topics of 'Practical considerations for the use of SGLT-2 inhibitors in the Asia–Pacific countries—An expert consensus statement'. Together they form a unique fingerprint.

Cite this